Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Bigazzi

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 24, 2012
Tangier disease: epidemiology, pathophysiology, and managementMariarita Puntoni, Francesco Sbrana, Federico Bigazzi, et al.
Future Cardiology|October 7, 2009
HDL inflammation and atherosclerosis: current and future perspectivesTiziana Sampietro, Federico Bigazzi, Mariarita Puntoni, et al.
Journal of Clinical Apheresis|April 4, 2025
Lipoprotein(a) Measurement in Lipoprotein Apheresis: Time to Change?Carmen Corciulo, Beatrice Dal Pino, Francesco Sbrana, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|October 22, 2021
Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis and PCSK9 inhibitorsBeatrice Dal Pino, Francesco Sbrana, Federico Bigazzi, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 24, 2023
Alirocumab in lipoprotein apheresis: A synergy for patients with high-Lp(a)Francesco Sbrana, Federico Bigazzi, Andrea Ripoli, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|November 28, 2023
Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemiaFrancesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, et al.
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|July 15, 2005
[High-density lipoproteins: the "new" target of cardiovascular medicine]Tiziana Sampietro, Federico Bigazzi, Beatrice Dal Pino, et al.
International Journal of Cardiology|June 28, 2005
HDL: the 'new' target of cardiovascular medicineTiziana Sampietro, Federico Bigazzi, Beatrice Dal Pino, et al.
Recenti Progressi in Medicina|June 27, 2009
[Heart without HDL.Tangier disease]Maria Rita Puntoni, Federico Bigazzi, Francesco Sbrana, et al.
Endocrine|June 30, 2025
Experience with apheretic treatment in the chronic management of severe hypertriglyceridemia: case seriesFrancesco Sbrana, Beatrice Dal Pino, Carmen Corciulo, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 24, 2012
Tangier disease: epidemiology, pathophysiology, and managementMariarita Puntoni, Francesco Sbrana, Federico Bigazzi, et al.
Future Cardiology|October 7, 2009
HDL inflammation and atherosclerosis: current and future perspectivesTiziana Sampietro, Federico Bigazzi, Mariarita Puntoni, et al.
Journal of Clinical Apheresis|April 4, 2025
Lipoprotein(a) Measurement in Lipoprotein Apheresis: Time to Change?Carmen Corciulo, Beatrice Dal Pino, Francesco Sbrana, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|October 22, 2021
Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis and PCSK9 inhibitorsBeatrice Dal Pino, Francesco Sbrana, Federico Bigazzi, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 24, 2023
Alirocumab in lipoprotein apheresis: A synergy for patients with high-Lp(a)Francesco Sbrana, Federico Bigazzi, Andrea Ripoli, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|November 28, 2023
Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemiaFrancesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, et al.
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|July 15, 2005
[High-density lipoproteins: the "new" target of cardiovascular medicine]Tiziana Sampietro, Federico Bigazzi, Beatrice Dal Pino, et al.
International Journal of Cardiology|June 28, 2005
HDL: the 'new' target of cardiovascular medicineTiziana Sampietro, Federico Bigazzi, Beatrice Dal Pino, et al.
Recenti Progressi in Medicina|June 27, 2009
[Heart without HDL.Tangier disease]Maria Rita Puntoni, Federico Bigazzi, Francesco Sbrana, et al.
Endocrine|June 30, 2025
Experience with apheretic treatment in the chronic management of severe hypertriglyceridemia: case seriesFrancesco Sbrana, Beatrice Dal Pino, Carmen Corciulo, et al.
Pageof 4